Back to top

3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock
September 05, 2017

Read MoreHide Full Article

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.

This method discovered several great candidates for momentum-oriented investors, but today let’s focus on Galmed Pharmaceuticals Ltd. (GLMD - Free Report) as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for GLMD’s status as a solid momentum stock below:

Longer Term Price Change for Galmed Pharmaceuticals

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. That is why looking at longer term price metrics—such as performance over the past three months or year-- and comparing these to an industry at large can be very useful.

And in the case of GLMD, the results are quite impressive. The company has beaten the industry at large over the past 12 weeks by a margin of 63.2% to 0, while it has also outperformed when looking at the past year, putting up a gain of 113.5%. Clearly, GLMD is riding a bit of a hot streak and is worth a closer look by investors.

Quarter EPS Estimate Change for Galmed Pharmaceuticals Stock

While looking at price performance or full year earnings can be essential to understanding a momentum stock, you shouldn’t forget about the current quarter EPS and the trend in estimates there. This change can signal how a stock might perform in the next earnings season, which is obviously vital for momentum investors.

Right now, GLMD is seeing a nice trend over the past month when it comes to this quarter’s earnings estimate projections. In the time frame, EPS estimates for Galmed Pharmaceuticals have gone up by 7.4% compared to a flat industry average move, suggesting that not only is GLMD heading in the right direction, but it is seeing an increase relative to the industry too.

GLMD Earnings Estimate Revisions Moving in the Right Direction

While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with GLMD as of late.

Over the past two months, two earnings estimates have gone higher compared to none lower for the full year, while we are also seeing that two estimate has move upwards with no downward revision for the next year time frame. These revisions have helped to boost the consensus estimate, as two months ago, GLMD was expected to post a loss of $1.37 per share for the full year, though today it is expected to post a loss of $1.19 for the full year, representing a solid increase which is something that should be welcome news to would-be investors.

Bottom Line

Given these factors, investors shouldn’t be surprised to note that we have GLMD as a security with a Zacks Rank #2 (Buy) and a Momentum Score of A.You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep GLMD on your short list as this looks be a stock that is very well-positioned to soar in the near term.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Galmed Pharmaceuticals Ltd. (GLMD) - free report >>


More from Zacks Tale of the Tape

You May Like